Protective Activity of Ingavirin® in Experimental Lethal Influenza Due to Pandemic Influenza Virus A (H1N1)v (Albino Mice)
Abstract
Despite obvious success in the vaccine development and chemotherapy of influenza, it remains a poorly controlled infection leading to emergence of new pandemic variants of the virus with high morbidity and mortality. We investigated the protective activity of Ingavirin® against the lethal influenza A(H1N1)2009 virus infection on albine mice. Oral use of Ingavirin® resulted in sharp decreasing of the mortality (index of protection up to 57%), slight decreasing of the infectious titer of the virus in the lungs (up to 40-fold), normalizing of the body weight dynamics and the lung tissue structure vs. the placebo-treated control. The degree of the bronchial epithelium damage was also strongly decreased. The results allow to consider Ingavirin® as an effective antiviral against the current pandemic influenza virus.
About the Authors
V. V. Zarubaev
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
A. V. Garshinina
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
N. A. Kalinina
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
A. A. Shtro
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
S. V. Belyaevskaya
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. E. Nebolsin
JSC Valenta Pharma
Russian Federation
Russian Federation
O. I. Kiselev
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Ghendon Y. Influenza - its impact and control. World Health Statistic Q 1992; 45: 306-311.
2. Zambon M. C. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999; 44: Suppl B: 3-9.
3. Scholtissek C., Quack G., Klenk H. D., Webster R. G. Antiviral Res 1998; 37: 83.
4. Woodhead M., Lavanchy D., Johnston S. et al. Neuraminidase inhibitors: progress in the management of influenza. Int J Clin Pract 2000 Nov; 54: 9: 604-610.
5. Kakugawa S., Shimojima M., Neumann G. et al. RuvB-like protein 2 is a suppressor of influenza A virus polymerases. J Virol 2009 Jul; 83: 13: 6429-6434.
6. Семенова Н. П., Прокудина Е. H., Львов Д. К., Небольсин В. Е. Влияние противовирусного препарата Ингавирин® на внутриклеточные преобразования и импорт в ядро нуклеокапсидного белка (NP) вируса гриппа. Вопросы вирусол 2010 (в печати).
7. Ludwig S., Planz O., Pleschka S., Wolff T. Influenza-virus-induced signalling cascades: targets for antiviral therapy? Trends in Molecular Medicine 2003; 9: 46-52.
8. Naveen Kumar, Zhong-tao Xin, Yuhong Liang et al. Signalling differentially regulates influenza virus RNA synthesis. J Virol 2008; 82: 20: 9880-9889.
9. David S. Fedson. Confronting the next influenza pandemic with antiinflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza and other Respiratory Viruses 3: 129-142.
Review
For citations:
Zarubaev V.V., Garshinina A.V., Kalinina N.A., Shtro A.A., Belyaevskaya S.V., Nebolsin V.E., Kiselev O.I. Protective Activity of Ingavirin® in Experimental Lethal Influenza Due to Pandemic Influenza Virus A (H1N1)v (Albino Mice). Antibiot Khimioter = Antibiotics and Chemotherapy. 2010;55(5-6):24-31. (In Russ.)
Views:
428
Email this article 